Both post-implant monotherapies in the trial achieved non-inferiority compared to dual anti-platelet therapy (DAPT) supporting the potential to simplify post-procedure drug regimens MARLBOROUGH, Mass. and SAN DIEGO, Nov. 2, 2026 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX)…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
